Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.23 · Revenue $0.00 · 4 analysts
Est. EPS $-0.24 · Revenue $0.00 · 4 analysts
Est. EPS $-1.02 · Revenue $2.96M · 4 analysts
Est. EPS $-0.26 · Revenue $0.00 · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-26.4M | -39.2% | -16.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-16.0M | -30.7% | +30.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.0% | — | — |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.38x | +14.0% | -25.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $31.7M | +70.4% | -11.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.32 vs -1.32 | +0.3% | -0.30 vs -0.26 | -14.5% |
| Revenue Surprise | $0 vs $23.1M | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | Carson Michael J. | officer: Vice President, Finance | Common Stock | A | 30,000 | — |
| Jun 30, 2026 | Mosseri Marlio Charles | 10 percent owner | Common Stock | A | 50,000 | $18.32 |
| Jun 30, 2026 | BENTSUR RON | director, 10 percent owner, officer: Chairman & CEO | Common Stock | A | 12,500 | $20.00 |
| Jun 11, 2026 | Hoberman Kenneth | director | Common Stock | A | 35,000 | — |
| Jun 11, 2026 | Oliviero James F III | director | Common Stock | A | 35,000 | — |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Ron Bentsur | Co-Founder, Chairman, Chief Executive Officer & President | USD 1,193,526 | Male | 1966 | Active |
Enrique Poradosu | Co-Founder, Executive Vice President, Chief Scientific & Business Officer | USD 749,241 | — | 1967 | Active |
Shay Shemesh | Co-Founder, Executive Vice President, Chief Development & Operations Officer | USD 749,241 | Male | 1984 | Active |
Michael Carson | Vice President of Finance | — | Male | 1976 | Active |
BlackRock Inc. bought a new position in shares of Nuvectis Pharma, Inc. (NASDAQ: NVCT) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,001,285 shares of the company's stock, valued at approximately $18,414,000. BlackRock Inc. owned approximately 3.07% of Nuvectis
Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET.
NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.
FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today reported its financial results for the second quarter of 2026 and provided an update on recent business progress.
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
